Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update.
- DOI
- 10.1080/14737167.2025.2479131
- Published
- 2025 Jun
- Container
- Expert review of pharmacoeconomics & outcomes research
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14737167.2025.2479131,
title = {Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update.},
author = {Tafuri G and Bracco A and Grueger J},
year = {2025},
journal = {Expert review of pharmacoeconomics \& outcomes research},
doi = {10.1080/14737167.2025.2479131},
url = {https://doi.org/10.1080/14737167.2025.2479131}
}RIS
TY - JOUR TI - Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update. AU - Tafuri G AU - Bracco A AU - Grueger J PY - 2025 JO - Expert review of pharmacoeconomics & outcomes research DO - 10.1080/14737167.2025.2479131 UR - https://doi.org/10.1080/14737167.2025.2479131 ER -
APA
G, T., A, B., & J, G. (2025). Access and pricing of medicines for patients with rare diseases in the European Union: an industry perspective. A 2025 update.. Expert review of pharmacoeconomics & outcomes research. https://doi.org/10.1080/14737167.2025.2479131
Source records
- pubmed · retrieved 2026-09-27T15:03:01.391Z